MA25325A1 - Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent. - Google Patents

Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.

Info

Publication number
MA25325A1
MA25325A1 MA26228A MA26228A MA25325A1 MA 25325 A1 MA25325 A1 MA 25325A1 MA 26228 A MA26228 A MA 26228A MA 26228 A MA26228 A MA 26228A MA 25325 A1 MA25325 A1 MA 25325A1
Authority
MA
Morocco
Prior art keywords
formulation
production method
same
multiple units
units containing
Prior art date
Application number
MA26228A
Other languages
English (en)
Inventor
Anders Ringberg
Torkel Gren
Martin Wikberg
Randy J Wald
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA25325(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/fr
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of MA25325A1 publication Critical patent/MA25325A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA26228A 1998-11-11 2001-06-08 Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent. MA25325A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (fr) 1998-08-27 1999-08-26 Formulation de tolterodine therapeutique a liberation controlee

Publications (1)

Publication Number Publication Date
MA25325A1 true MA25325A1 (fr) 2001-12-31

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26228A MA25325A1 (fr) 1998-11-11 2001-06-08 Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.

Country Status (40)

Country Link
US (1) US6911217B1 (fr)
EP (1) EP1128819B1 (fr)
JP (1) JP3616011B2 (fr)
KR (1) KR100467384B1 (fr)
CN (1) CN1169522C (fr)
AP (1) AP1323A (fr)
AR (1) AR027815A1 (fr)
AT (1) ATE247458T1 (fr)
AU (1) AU762410B2 (fr)
BG (1) BG65149B1 (fr)
BR (1) BRPI9915142B8 (fr)
CA (1) CA2350061C (fr)
CZ (1) CZ299582B6 (fr)
DE (1) DE69910604T2 (fr)
DK (1) DK1128819T3 (fr)
EA (1) EA005074B1 (fr)
EE (1) EE05232B1 (fr)
ES (1) ES2204193T3 (fr)
GE (1) GEP20022833B (fr)
HK (1) HK1040917B (fr)
HR (1) HRP20010333B1 (fr)
HU (1) HU226582B1 (fr)
ID (1) ID30039A (fr)
IL (1) IL142809A0 (fr)
IS (1) IS2370B (fr)
MA (1) MA25325A1 (fr)
MY (1) MY122195A (fr)
NO (1) NO331399B1 (fr)
NZ (1) NZ511430A (fr)
OA (1) OA11673A (fr)
PL (1) PL195780B1 (fr)
PT (1) PT1128819E (fr)
RS (1) RS49891B (fr)
SE (1) SE9803871D0 (fr)
SI (1) SI1128819T1 (fr)
SK (1) SK284758B6 (fr)
TW (2) TWI267385B (fr)
UA (1) UA57165C2 (fr)
WO (1) WO2000027364A1 (fr)
ZA (1) ZA200103575B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728395B2 (en) * 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (fr) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
CZ304671B6 (cs) 1999-11-11 2014-08-27 Pharmacia Ab Farmaceutický prostředek obsahující tolterodin a jeho použití
CA2496806A1 (fr) * 2002-08-28 2004-03-11 Pharmacia Corporation Composition liquide de tolterodine administree par voie orale
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
ES2324712T5 (es) * 2003-01-22 2012-06-08 Pfizer Health Ab Dosis reducida de tolterodina para tratar trastornos urinarios
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
DK2210605T3 (en) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
JP4771956B2 (ja) 2003-11-04 2011-09-14 スパーナス ファーマシューティカルズ インコーポレイテッド バイオアベイラビリティーエンハンサを含む第四級アンモニウム化合物の組成物
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (fr) † 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Composition pharmaceutique de tolterodine avec liberation soutenue
TW200640839A (en) * 2005-01-10 2006-12-01 Teva Pharma Process for preparing Tolterodine tartrate
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
TR201902010T4 (tr) 2006-01-18 2019-03-21 Intec Pharma Ltd Bir ajanın oral alımına yönelik taşıyıcı cihaz.
CA2882048C (fr) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
JP2009527554A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド コハク酸メトプロロールｅ．ｒ．の錠剤およびその調製方法
JP2009530397A (ja) * 2006-03-21 2009-08-27 テバ ファーマシューティカル インダストリーズ リミティド トルテロジンの調節された開放性製剤
EP1839649A1 (fr) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Formulations enrobées pour tolterodine
WO2007112581A1 (fr) * 2006-04-03 2007-10-11 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
EP2015735A1 (fr) * 2006-04-21 2009-01-21 Synthon B.V. Perles de tolterodine
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007131804A1 (fr) 2006-05-17 2007-11-22 Synthon B.V. Composition en comprimé pour la libération prolongée de la tamsulosine
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
CA2670636A1 (fr) 2006-11-27 2008-06-05 H. Lundbeck A/S Derives d'heteroaryl-amides
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
EP3542792B1 (fr) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Libération contrôlée de 25-hydroxyvitamine d
WO2008134523A1 (fr) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Procédé sûr et efficace de traitement et de prévention de l'hyperparathyroïdie secondaire dans les maladies rénales chroniques
EP2173329A1 (fr) * 2007-07-03 2010-04-14 Synthon B.V. Bille de toltérodine
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
WO2009019599A2 (fr) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Compositions à libération prolongée comprenant de la toltérodine
ES2692437T3 (es) 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Fármacos resistentes al abuso, método de uso y método de preparación
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (fr) * 2008-04-01 2009-10-01 Pharmascience Inc. Nouvelles formulations pharmaceutiques orales a liberation controlee
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
WO2009140557A2 (fr) * 2008-05-14 2009-11-19 Capricorn Pharma, Inc. Formulations de toltérodine à libération modifiée
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
CA2769760A1 (fr) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Compositions pharmaceutiques a unites multiples multi-couches
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011061616A2 (fr) 2009-11-23 2011-05-26 Micro Labs Limited Compositions à libération prolongée contenant de la toltérodine et procédé de préparation de celles-ci
WO2011095388A1 (fr) 2010-02-04 2011-08-11 Synthon Bv Microgranule de toltérodine
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
HUE048464T2 (hu) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Módszerek és készítmények mellékpajzsmirigy szintjének csökkentésére
PL2552418T3 (pl) 2010-03-29 2017-12-29 Ferring B.V. Szybko rozpuszczająca się kompozycja farmaceutyczna
EP2563123B1 (fr) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Nouveaux agonistes du récepteur bêta 3 adrénergique
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120289560A1 (en) * 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2013037708A1 (fr) 2011-09-16 2013-03-21 Ferring B.V. Composition pharmaceutique à dissolution rapide
WO2013047795A1 (fr) * 2011-09-30 2013-04-04 アステラス製薬株式会社 Composition pharmaceutique granulaire
EP2872177B1 (fr) 2012-07-12 2017-12-20 Ferring BV Formulations de diclofénac
MX2015003658A (es) * 2012-09-20 2015-09-25 Ohr Pharma Llc Microparticulas biodegradables de capas multiples para la liberacion sostenida de agentes terapeuticos.
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
EP2968579B1 (fr) * 2013-03-13 2020-04-15 Intervet International B.V. Substances bioactives stables et procédés de fabrication
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
CA2957240A1 (fr) 2014-08-07 2016-02-11 Opko Ireland Global Holdings, Ltd. Therapie d'appoint avec de la 25-hydroxyvitamine d
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2902911C (fr) * 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US20190083628A1 (en) * 2016-02-23 2019-03-21 Nipro Corporation Pharmaceutical composition particles and orally disintegrating preparation including the same
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
KR100467384B1 (ko) 2005-01-24
BG105582A (en) 2001-12-29
SK6252001A3 (en) 2002-01-07
EP1128819A1 (fr) 2001-09-05
ATE247458T1 (de) 2003-09-15
CA2350061A1 (fr) 2000-05-18
EE200100254A (et) 2002-12-16
TWI222879B (en) 2004-11-01
NO20012314D0 (no) 2001-05-10
RS49891B (sr) 2008-08-07
ZA200103575B (en) 2002-05-03
SK284758B6 (sk) 2005-11-03
HK1040917B (zh) 2005-05-27
DE69910604D1 (de) 2003-09-25
BRPI9915142B8 (pt) 2021-05-25
SI1128819T1 (en) 2003-12-31
AP1323A (en) 2004-11-05
EA200100538A1 (ru) 2001-10-22
MY122195A (en) 2006-03-31
CZ299582B6 (cs) 2008-09-10
DK1128819T3 (da) 2003-12-01
PL195780B1 (pl) 2007-10-31
JP3616011B2 (ja) 2005-02-02
YU33101A (sh) 2003-10-31
EE05232B1 (et) 2009-12-15
PL348612A1 (en) 2002-06-03
TWI267385B (en) 2006-12-01
DE69910604T2 (de) 2004-06-24
HRP20010333B1 (en) 2004-10-31
GEP20022833B (en) 2002-11-25
WO2000027364A1 (fr) 2000-05-18
NO331399B1 (no) 2011-12-19
UA57165C2 (uk) 2003-06-16
HUP0105038A2 (en) 2002-06-29
AU762410B2 (en) 2003-06-26
EP1128819B1 (fr) 2003-08-20
AR027815A1 (es) 2003-04-16
CZ20011627A3 (cs) 2001-10-17
SE9803871D0 (sv) 1998-11-11
CN1169522C (zh) 2004-10-06
BR9915142A (pt) 2001-08-07
CA2350061C (fr) 2005-05-17
BRPI9915142B1 (pt) 2015-08-25
CN1326339A (zh) 2001-12-12
AP2001002166A0 (en) 2001-06-30
HRP20010333A2 (en) 2003-04-30
BG65149B1 (bg) 2007-04-30
NO20012314L (no) 2001-07-09
JP2003517446A (ja) 2003-05-27
HUP0105038A3 (en) 2006-07-28
IS5936A (is) 2001-05-09
PT1128819E (pt) 2003-12-31
NZ511430A (en) 2003-05-30
ES2204193T3 (es) 2004-04-16
HK1040917A1 (en) 2002-06-28
IS2370B (is) 2008-06-15
KR20010075695A (ko) 2001-08-09
IL142809A0 (en) 2002-03-10
US6911217B1 (en) 2005-06-28
EA005074B1 (ru) 2004-10-28
OA11673A (en) 2005-01-12
ID30039A (id) 2001-11-01
HU226582B1 (en) 2009-04-28
AU1436600A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
MA25325A1 (fr) Nouvelle gelule a dosage controle, la methode de production et la formulation des unites multiples qui la contiennent.
NO973922L (no) Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
MXPA03007712A (es) Sales farmaceuticas.
EE9700044A (et) Heteroarüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid.
HUP0200312A3 (en) Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
DE69102531D1 (de) Mikrokapseln, Verkapselungsverfahren und Methode zur Anwendung derselben.
FI925615A0 (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening
ZA965294B (en) Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containing them.
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
HRP20010115B1 (en) Benzocycloheptenes, method for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
HUP9800273A3 (en) Benzothiazine dioxides as endothelin antagonists, process for their production and pharmaceutical compositions containing the same
ZA983792B (en) New cysteine derivatives, processes for their production, and pharmaceuticals containing them.
WO2001058875A3 (fr) Derives substitues d'acide 1,2,3,4-tetrahydroquinoline-2-carboxylique
NO880473L (no) Fremgangsmaate til fremstilling av substituerte 3,4-dihydro-2h-benzopyraner og deres anvendelse som legemiddel.
NO883465L (no) Fremgangsmaate og mellomprodukter for fremstilling av 1-fenyl-3-(1-piperazinyl)-1h-indazoler, og anvendelse derav som medikamenter.
NO306156B1 (no) Substituerte benzyloksykarbonylguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum sÕvel som legemidler inneholdende disse
HUP9901376A3 (en) 1-methylcarbapenem derivatives, their use, production thereof and medicaments containing the same
ZA988711B (en) New tetracycles, process for their production and pharmaceutical preparations containing these compounds.
DE3481057D1 (de) 2-sulfamoylbenzo(b)thiophen-derivate, ihre herstellung und pharmazeutische zubereitung zur behandlung von erhoehtem augeninnendruck.
NO904576D0 (no) Aminopyridinylaminofenol og beslektede forbindelser, mellomprodukter, fremgangsmaate for deres fremstilling og anvendelse som medikamenter.
HUP9802731A3 (en) Vitamin d analogues, use thereof, medicaments containing them, their production
ATE125541T1 (de) Reine kristalline form von rifapentin.
IT8419657A0 (it) Farmaci contenenti muzolimin, loro impiego e procedimenti per la loro produzione.
NO306468B1 (no) Nye fosfolipid-derivater, deres fremstilling, legemiddel inneholdende derivatene og derivatenes anvendelse
NO894516D0 (no) Fremgangsmaate for fremstilling av 1-aminoalkyl-3-oksosubstituert-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-on, og deres anvendelse som medikamenter.